

EXHIBIT 20

Morgan Lewis

Rebecca J. Hillyer

Partner
+1.215.963.5160
rebecca.hillyer@morganlewis.com

February 22 2019

VIA E-MAIL

Peter H. Weinberger
Spangenberg Shibley & Liber LLP
1001 Lakeside Avenue East, Suite 1700
Cleveland, Ohio 44114
pweinberger@spanglaw.com

Evan M. Janush
Tower 56
126 East 56th Street, 6th Floor
New York, NY 10022
evan.janush@lanierlawfirm.com

RE: *In re National Prescription Opiate Litigation*, MDL No. 2804: Discovery Ruling No. 15
Regarding IQVIA Discovery

Dear Peter and Evan:

On behalf of Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Actavis LLC; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; and Watson Laboratories, Inc. (collectively, the "Teva Defendants"), we write this letter pursuant to Special Master Cohen's Discovery Ruling No. 15 regarding IQVIA discovery.¹

¹ Pursuant to Special Master Cohen's Discovery Ruling No. 15, "IQVIA" includes all related legacy entities, such as Dendrite, Cegedim, Cegedim Dendrite, and BuzzeoPDMA.

Morgan, Lewis & Bockius LLP

1701 Market Street
Philadelphia, PA 19103-2921
United States

T +1.215.963.5000
F +1.215.963.5001

February 22, 2019
Page 2

Since November 2018, the Teva Defendants' and IQVIA's counsel have worked closely to identify, collect, review, and produce a wide assortment of SOMS-related materials sought by Plaintiffs in a reasonable, cost-effective manner. To date, the Teva Defendants and IQVIA, both separately and together, have exerted tremendous efforts to satisfy Plaintiffs' frequent, continual, and burdensome demands regarding SOMS-related discovery. In fact, the PEC has already confirmed the Teva Defendants' compliance with producing requested information related to their SOMS programs several times. See, e.g., Linda Singer's January 7, 2019 email which contained the subject line: "Renewed agenda item re. manufacturers' SOMs and chargeback information." The Teva Defendants' production of SOMS-related documents within their possession, custody, or control is substantially complete, and the Teva Defendants will continue to produce responsive non-privileged documents identified in IQVIA's possession, custody, or control.

Status of the Teva Defendants' Facilitation of Discovery of Information from IQVIA – Contracts and/or Scope of Work Documents

On December 7, 2018, after undertaking significant burden and expense, IQVIA informed the Teva Defendants that IQVIA was able to provide the Teva Defendants with contracts and/or scope of work documents. In turn, on December 14, 2018, the Teva Defendants requested production from IQVIA of these materials. See Exhibit A.

On January 7, 2019, IQVIA's counsel provided the Teva Defendants with a set of readily accessible agreements between the Teva Defendants and only BuzzeoPDMA. See Exhibit B.

On January 9, 2019, the Teva Defendants renewed their request for production from IQVIA of contracts and/or scope of work documents for all IQVIA entities. See Exhibit B.

On January 10, 2019, IQVIA's counsel provided the Teva Defendants with an initial set of readily accessible agreements between the Teva Defendants and IQVIA. See Exhibit C.

On January 16, 2019, after IQVIA's counsel located additional contracts through extensive search and collection efforts, they provided the Teva Defendants with another set of readily accessible agreements between the Teva Defendants and IQVIA. See Exhibits D, E.

On January 26, 2019, IQVIA's counsel provided the Teva Defendants with another set of readily accessible agreements between the Teva Defendants and IQVIA. See Exhibit F.

On February 8, 2019, the Teva Defendants produced to Plaintiffs the contracts and scope of work documents received from IQVIA and that the Teva Defendants identified being within their possession, custody, or control at TEVA_MDL_A_13647097 – TEVA_MDL_A_13647828. See Exhibit G.

Status of the Teva Defendants' Facilitation of Discovery of Information from IQVIA – SOMS Data and Reports

On February 7, 2019, the Teva Defendants requested production from IQVIA of any SOMS-related reports or work product that IQVIA previously had provided to the Teva Defendants. See Exhibit H.

On February 8, 2019, the Teva Defendants' and IQVIA's counsel held a telephonic conference during which IQVIA's counsel stated they were working on collecting these materials. Then on February 15, 2019, IQVIA's counsel advised that they anticipated providing these materials that were readily accessible on February 22, 2019. See Exhibit I.

February 22, 2019
Page 3

As of the date of this letter, the Teva Defendants have not yet received these materials from IQVIA. To the extent the Teva Defendants receive additional responsive non-privileged documents from IQVIA, those documents will be produced.

Status of the Teva Defendants' Facilitation of Discovery of Information from IQVIA – Communications Between IQVIA and the Teva Defendants Concerning SOMS

On February 7, 2019, the Teva Defendants requested production from IQVIA of any communications concerning SOMS audits, SOMS design, and Suspicious Order Monitoring between IQVIA and the Teva Defendants ("SOMS Communications"). See Exhibit H.

On February 8, 2019, the Teva Defendants' and IQVIA's counsel held a telephonic conference during which IQVIA's counsel stated that the Teva Defendants' SOMS Communications request, similar to Plaintiffs' analog Rule 45 Subpoena request, was overly broad, not proportional to the needs of the case, and would impose undue burden and expense on IQVIA. See Exhibit I.

As of the date of this letter, the Teva Defendants have not yet received from IQVIA any SOMS Communications.

Status of the Teva Defendants' Production of IQVIA-Related Information Directly – Contracts and/or Scope of Work Documents

The Teva Defendants have produced all contracts and/or scope of work documents related to SOMS consulting services from IQVIA, that was provided by IQVIA's counsel and that the Teva Defendants identified being within their possession, custody, or control at TEVA_MDL_A_13647097 – TEVA_MDL_A_13647828. See Exhibit G.

Status of the Teva Defendants' Production of IQVIA-Related Information Directly – SOMS Data and Reports

After a reasonable investigation and examination of contracts, scope of work documents, and reports provided by IQVIA, the Teva Defendants are unaware of any SOMS-related data provided by IQVIA. The Teva Defendants have, however, collected and produced the following SOMS-related reports from IQVIA within the Teva Defendants' possession, custody, or control:

- The September 25, 2012 Cegedim report that begins with bates number TEVA_MDL_A_01060005;
- The July 14, 2013 BuzzeoPDMA report that begins with bates number TEVA_MDL_A_01464264; and
- The August 6, 2013 BuzzeoPDMA report that begins with bates number TEVA_MDL_A_01464245.

Status of the Teva Defendants' Production of IQVIA-Related Information Directly – Communications Between IQVIA and the Teva Defendants Concerning SOMS

Through reasonable efforts proportional to the needs of the matter, the Teva Defendants have produced the communications in their possession, custody, or control concerning SOMS.

The Teva Defendants have indicated on their weekly production chart, status reports, and production cover letters – as well as in numerous correspondence with Plaintiffs – that responsive documents concerning the Teva Defendants' SOMS program were produced. For example, as

February 22, 2019
Page 4

explained in Richard Shephard's email dated December 6, 2018, the Teva Defendants' ninth production (TEVA_MDL_A_01037081 – TEVA_MDL_A_01061119) contained over 10,000 documents which "included documents relating to suspicious order monitoring program, including certain files from Teva's DEA compliance folder, as well as hard copy documents." See Teva Production 9 (August 1, 2018) entry in Teva's Weekly Status Report. The Teva Defendants also have produced a wealth of custodial documents from agreed custodians from the DEA Compliance department, which oversees Teva's SOMS program.

In addition, the Teva Defendants' counsel combed through their production to identify specific communications between IQVIA and the Teva Defendants concerning SOMS. Exhibit J contains a list of the identified communications. This list was created through the Teva Defendants' reasonable efforts and does not purport to be an exhaustive list of all communications between IQVIA and the Teva Defendants concerning SOMS. The Teva Defendants reserve the right to modify this list if additional information is discovered but disclaim any continuing obligation to supplement it.

Status of the Teva Defendants' Production of IQVIA-Related Information Directly – Privilege Assertions

The Teva Defendants are not withholding SOMS-related documents or information based on any blanket assertion of privilege. The Teva Defendants have withheld documents or information related to SOMS only if such documents contain legal advice, requests for legal advice, provide information to counsel or compile information for counsel for the purposes of providing legal advice, or attorney work product. Subject to these privilege objections, the Teva Defendants have produced all the documents and information identified to-date responsive to Plaintiffs' SOMS discovery requests.

Please let us know if further assistance is needed.

Sincerely,

/s/ Rebecca J. Hillyer

Rebecca J. Hillyer

c: *via e-mail*
mdl2804discovery@motleyrice.com
xALLDEFENDANTS-MDL2804-Service@arnoldporter.com

EXHIBIT A

Shephard, Jr., Richard G.

From: Jacobs, Evan K.
Sent: Friday, December 14, 2018 9:16 AM
To: Oot, Patrick L. (SHB)
Cc: Shephard, Jr., Richard G.; Hillyer, Rebecca J.
Subject: RE: IQVIA's clients affected by the In re National Prescription Opiate Litigation, MDL No. 2804

Patrick,

Thank you for your December 7, 2018 letter. On behalf of our clients Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Actavis LLC, Actavis Pharma, Inc., and Watson Laboratories, Inc., we would like to request the readily accessible contracts that IQVIA has been able to identify. You can send the secure file download to my colleague Richard Shephard (copied here) and me.

Per your letter, if we produce these contracts in the MDL we will designate them as "Highly Confidential – Subject to Protective Order" and will otherwise treat the contracts as *Attorneys' Eyes Only*.

Please let me know if you need any additional information to provide IQVIA's readily accessible contracts. Thank you for your assistance in this matter.

Evan Jacobs

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Oot, Patrick L. (SHB) <OOT@shb.com>
Sent: Friday, December 07, 2018 11:08 PM
To: 'Rice, Dale' <drice@cov.com>; tmtabacchi@jonesday.com; Joshua.Davis@arnoldporter.com; Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Wilson, Brittany (SHB) <BWilson@shb.com>
Cc: smiller@zuckerman.com; 'Andrew.O'Connor@ropesgray.com' <Andrew.O'Connor@ropesgray.com>; 'arollins@reedsmith.com' <arollins@reedsmith.com>; 'brandan.montminy@lockelord.com' <brandan.montminy@lockelord.com>; 'bcole@bakerdonelson.com' <bcole@bakerdonelson.com>; 'cgp@pelini-law.com' <cgp@pelini-law.com>; 'pbricard@pelini-law.com' <pbricard@pelini-law.com>; Carmeli, Daniel <daniel.carmeli@morganlewis.com>; 'dean.barnhard@btlaw.com' <dean.barnhard@btlaw.com>; sbaglin@omm.com; 'elewis@ccealaw.com' <elewis@ccealaw.com>; 'jpiltch@foley.com' <jpiltch@foley.com>; 'jennifer.levy@kirkland.com' <jennifer.levy@kirkland.com>; 'catie.ventura@kirkland.com'; Joe.Franco@hkllaw.com; 'jonathan.stern@arnoldporter.com' <jonathan.stern@arnoldporter.com>; kaspar.stoffelmayer@bartlit-beck.com; 'lmiller@jacksonkelly.com' <lmiller@jacksonkelly.com>; 'mrodgers@cov.com' <mrodgers@cov.com>; Paul.Lafata@dechert.com; 'sda@ramlaw.com' <sda@ramlaw.com>; 'TJohnson@cavitch.com' <TJohnson@cavitch.com>; 'tchapman@bakerlaw.com' <tchapman@bakerlaw.com>; 'nwadhwani@wc.com' <nwadhwani@wc.com>; Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Jacobs, Evan K. <evan.jacobs@morganlewis.com>
Subject: IQVIA's clients affected by the In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Good evening everyone.

Many of you have reached out to us seeking information from IQVIA. In response, we have worked with our client to prepare the attached.

I asked Dale, Tina and Josh to act as liaison counsel for IQVIA with their respective defense counsel groups to streamline the conversation and distribute this as needed. We are very appreciative for that.

Please review – it should answer many questions.

Have a nice weekend.

Best,

Patrick

Patrick L. Oot

Partner & Co-Chair, Data and Discovery Strategies

Shook, Hardy & Bacon L.L.P.

o: 202.639.5645 | oot@shb.com



EXHIBIT B

Shephard, Jr., Richard G.

From: Jacobs, Evan K.
Sent: Wednesday, January 09, 2019 10:12 PM
To: Shoshtari, Adam M. (SHB); Oot, Patrick L. (SHB)
Cc: Feinstein, Wendy West; Hillyer, Rebecca J.; Shephard, Jr., Richard G.; Hammoud, Adam
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Adam,

Thanks for these documents. On our initial review, it looks like these contracts all relate to work with Buzzeo. Can IQVIA also provide the Teva Defendants (Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc. and Actavis LLC) with its reasonable accessible contracts/engagement agreements outside of just Buzzeo (e.g., contracts with IQVIA/IMS).

This was the request we made on December 14 in response to Patrick's December 7 letter offering to provide these contracts.

Thank you very much for your assistance.

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Monday, January 07, 2019 5:33 PM

To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Evan—

As previously requested, you will be receiving a secure link and password in order to download the readily accessible agreements. These will come in **two separate e-mails**, and should be distributed shortly. We are doing another follow-up with the client later this week, but this is what we have located after a reasonable search. I will be in touch as to whether you should be expecting anything further.

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Shoshtari, Adam M. (SHB)
Sent: Friday, January 4, 2019 3:31 PM
To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <oot@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Hi Evan—

We are still working with our client on your request, but hope to have information for you early next week.

I will follow-up as soon as possible.

Have a nice weekend!

Best,

Adam M. Shoshtari
Staff Attorney
Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>
Sent: Thursday, January 3, 2019 9:16 AM
To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Thanks, Adam. Much appreciated. Just to clarify, in addition to the Buzzeo related agreements we are also interested in any other agreements/statements of work/engagements that IQVIA has been able to identify based on their reasonable search (we sent an email on December 14 in response to Patrick's Dec. 7 letter requesting agreements generally) . We very much appreciate your assistance.

Happy New Year!

Evan

Evan K. Jacobs
Morgan, Lewis & Bockius LLP
1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001
evan.jacobs@morganlewis.com | www.morganlewis.com
Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Thursday, January 03, 2019 9:11 AM

To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Evan—

Happy New Year!

We are working on your request and I will follow-up tomorrow!

In addition, and per our objections, we have directed Plaintiffs to contact Defendants and right now, have not agreed to produce any information directly to Plaintiffs. The goal of our notice was to inform IQVIA clients of the request, identify the engagements that we are aware of after a reasonable search and to help clients respond from their own sources.

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>

Sent: Monday, December 31, 2018 10:46 AM

To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: FW: In re National Prescription Opiate Litigation, MDL No. 2804

Adam and Patrick,

Happy New Year! Thanks for the information in the attached letters. We are continuing to work with our client to identify these agreements, but have not been able to do so yet. Are you able to send copies of the Agreements/Statement of Work that are referenced in your letters? In addition, to the extent you may be producing work product from these engagements, could you please send us copies of what you plan to produce?

Happy to discuss if you have any questions. Thanks for all of your assistance,

Evan

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Wednesday, December 19, 2018 8:35 PM

To: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>

Cc: Oot, Patrick L. (SHB) <OOT@shb.com>

Subject: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Wendy—

See attached on behalf of IQVIA, Inc.

Happy Holidays!

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



Mail Gate made the following annotations on Wed Dec 19 2018 19:35:11

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

DISCLAIMER

This e-mail message is intended only for the personal use of the recipient(s) named above. This message may be an attorney-client communication and as such privileged and confidential and/or it may include attorney work product. If you are not an intended recipient, you may not review, copy or distribute this message. If you have received this communication in error, please notify us immediately by e-mail and delete the original message.

Mail Gate made the following annotations on Thu Jan 03 2019 08:10:54

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person

or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

Mail Gate made the following annotations on Mon Jan 07 2019 16:32:31

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

EXHIBIT C

From: GoA Services Admin EDS LV <gaslv@epiqsystems.com>
Sent: Thursday, January 10, 2019 3:26 PM
To: Jacobs, Evan K.
Subject: IQVIA: Contracts\Teva

[EXTERNAL EMAIL]

Secure Delivery

The following file(s) have been sent to you from jpalomo@epiqglobal.com. To download, please click on the following link.

[Click here to download the file\(s\) listed below](#)

Teva 001.rar 16.19 MB

If the link above does not open, please copy and paste the following URL into your browser:
<https://transfer.epiqsystems.com/pkg?token=afac39ba-6771-4462-ade7-b872dbcc9a81>

This email is confidential and is intended solely for the use of the named addresses.
This notification has been sent to you by [GoAnywhere Services](#).

This communication (including any attachment(s)) is intended solely for the recipient(s) named above and may contain information that is confidential, privileged or legally protected. Any unauthorized use or dissemination of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by return e-mail message and delete all copies of the original communication to include any copy that may reside in your sent box. Thank you for your cooperation.

EXHIBIT D

From: GoA Services Admin EDS LV <gaslv@epiqsystems.com>
Sent: Wednesday, January 16, 2019 5:18 PM
To: Jacobs, Evan K.
Subject: IQVIA - ATC

Follow Up Flag: Follow up
Flag Status: Completed

[EXTERNAL EMAIL]

Secure Delivery

The following file(s) have been sent to you from jpalomo@epiqglobal.com. To download, please click on the following link.

[Click here to download the file\(s\) listed below](#)

ATC 002.zip 13.22 MB

If the link above does not open, please copy and paste the following URL into your browser:
<https://transfer.epiqsystems.com/pkg?token=82b73d2e-2c74-4d6e-8043-e01e7f1dff71>

This email is confidential and is intended solely for the use of the named addresses.
This notification has been sent to you by [GoAnywhere Services](#).

This communication (including any attachment(s)) is intended solely for the recipient(s) named above and may contain information that is confidential, privileged or legally protected. Any unauthorized use or dissemination of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by return e-mail message and delete all copies of the original communication to include any copy that may reside in your sent box. Thank you for your cooperation.

EXHIBIT E

Shephard, Jr., Richard G.

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>
Sent: Tuesday, January 15, 2019 7:31 AM
To: Jacobs, Evan K.; Oot, Patrick L. (SHB)
Cc: Feinstein, Wendy West; Hillyer, Rebecca J.; Shephard, Jr., Richard G.; Hammoud, Adam
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Evan—

I hope all is well!

IQVIA has located additional Buzzeo and Cegedim Dendrite agreements. We are in the process of redacting pricing information (as per standard practice) and should have these available for you to download (via a secure link) tomorrow.

Best,

Adam M. Shoshtari

Staff Attorney
Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Shoshtari, Adam M. (SHB)
Sent: Wednesday, January 9, 2019 10:42 PM
To: 'Jacobs, Evan K.' <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <oot@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Hi Evan—

These will be shared with you (via Epiq) tomorrow.

Have a nice evening!

Best,

Adam M. Shoshtari

Staff Attorney
Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>

Sent: Wednesday, January 9, 2019 10:12 PM

To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Adam,

Thanks for these documents. On our initial review, it looks like these contracts all relate to work with Buzzeo. Can IQVIA also provide the Teva Defendants (Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc. and Actavis LLC) with its reasonable accessible contracts/engagement agreements outside of just Buzzeo (e.g., contracts with IQVIA/IMS).

This was the request we made on December 14 in response to Patrick's December 7 letter offering to provide these contracts.

Thank you very much for your assistance.

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Monday, January 07, 2019 5:33 PM

To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Evan—

As previously requested, you will be receiving a secure link and password in order to download the readily accessible agreements. These will come in **two separate e-mails**, and should be distributed shortly. We are doing another follow-up with the client later this week, but this is what we have located after a reasonable search. I will be in touch as to whether you should be expecting anything further.

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Shoshtari, Adam M. (SHB)
Sent: Friday, January 4, 2019 3:31 PM
To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <oot@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Hi Evan—

We are still working with our client on your request, but hope to have information for you early next week.

I will follow-up as soon as possible.

Have a nice weekend!

Best,

Adam M. Shoshtari
Staff Attorney
Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>
Sent: Thursday, January 3, 2019 9:16 AM
To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Thanks, Adam. Much appreciated. Just to clarify, in addition to the Buzzeo related agreements we are also interested in any other agreements/statements of work/engagements that IQVIA has been able to identify based on their reasonable search (we sent an email on December 14 in response to Patrick's Dec. 7 letter requesting agreements generally) . We very much appreciate your assistance.

Happy New Year!

Evan

Evan K. Jacobs
Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921
Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001
evan.jacobs@morganlewis.com | www.morganlewis.com
Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>
Sent: Thursday, January 03, 2019 9:11 AM
To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <OOT@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]
Hi Evan—

Happy New Year!

We are working on your request and I will follow-up tomorrow!

In addition, and per our objections, we have directed Plaintiffs to contact Defendants and right now, have not agreed to produce any information directly to Plaintiffs. The goal of our notice was to inform IQVIA clients of the request, identify the engagements that we are aware of after a reasonable search and to help clients respond from their own sources.

Best,

Adam M. Shoshtari
Staff Attorney
Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>
Sent: Monday, December 31, 2018 10:46 AM
To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: FW: In re National Prescription Opiate Litigation, MDL No. 2804

Adam and Patrick,

Happy New Year! Thanks for the information in the attached letters. We are continuing to work with our client to identify these agreements, but have not been able to do so yet. Are you able to send copies of the Agreements/Statement of Work that are referenced in your letters? In addition, to the extent you may be producing work product from these engagements, could you please send us copies of what you plan to produce?

Happy to discuss if you have any questions. Thanks for all of your assistance,

Evan

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Wednesday, December 19, 2018 8:35 PM

To: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>

Cc: Oot, Patrick L. (SHB) <OOT@shb.com>

Subject: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Wendy—

See attached on behalf of IQVIA, Inc.

Happy Holidays!

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



Mail Gate made the following annotations on Wed Dec 19 2018 19:35:11

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

DISCLAIMER

This e-mail message is intended only for the personal use of the recipient(s) named above. This message may be an attorney-client communication and as such privileged and confidential and/or it may include attorney work product. If you are not an intended recipient, you may not review, copy or distribute this message. If you have received this communication in error, please notify us immediately by e-mail and delete the original message.

Mail Gate made the following annotations on Thu Jan 03 2019 08:10:54

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

Mail Gate made the following annotations on Mon Jan 07 2019 16:32:31

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

Mail Gate made the following annotations on Tue Jan 15 2019 06:31:21

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

EXHIBIT F

From: GoA Services Admin EDS LV <gaslv@epiqsystems.com>
Sent: Saturday, January 26, 2019 2:09 PM
To: Jacobs, Evan K.
Subject: IQVIA - ATC

[EXTERNAL EMAIL]

Secure Delivery

The following file(s) have been sent to you from jpalomo@epiqglobal.com. To download, please click on the following link.

[Click here to download the file\(s\) listed below](#)

ATC 003.zip 1.27 MB

If the link above does not open, please copy and paste the following URL into your browser:
<https://transfer.epiqsystems.com/pkg?token=4e4ad061-573d-4cb0-878a-07bab7007d9c>

This email is confidential and is intended solely for the use of the named addresses.
This notification has been sent to you by [GoAnywhere Services](#).

This communication (including any attachment(s)) is intended solely for the recipient(s) named above and may contain information that is confidential, privileged or legally protected. Any unauthorized use or dissemination of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by return e-mail message and delete all copies of the original communication to include any copy that may reside in your sent box. Thank you for your cooperation.

EXHIBIT G

Morgan Lewis

Rebecca J. Hillyer

Partner
+1.215.963.5160
rebecca.hillyer@morganlewis.com

February 8, 2019

VIA E-MAIL

Peter H. Weinberger, Esq.
Spangenberg Shibley & Liber
1001 Lakeside Avenue East
Suite 1700
Cleveland, OH 44114

RE: In Re National Prescription Opiate Litigation
Case No. 1:17-MD-2804
Sixtieth Production (TEVA MDL A PROD060)

Dear Peter:

On behalf of Cephalon, Inc. and Teva Pharmaceuticals USA, Inc. (collectively, "Teva") and Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc. f/k/a Watson Pharma, Inc. (collectively, the "Acquired Actavis Entities"), we have produced via secure file transfer to Ricoh a production of 77 documents Bates labeled TEVA_MDL_A_13647097 – TEVA_MDL_A_13647828. These documents are being produced in response to Case Management Order One (Docket No. 232), entered by the Court on April 11, 2018. This production consists of contracts and statements of work related to services provided by IQVIA and its related entities.

The production is encrypted and the password to access it is: eAGJ8xU-73t2bp\$3.

Teva and the Acquired Actavis Entities are producing the enclosed documents and information with the understanding that you will afford the protections provided by the Case Management Order Two: Protective Order (Docket No. 441), entered by the Court on May 15, 2018.

To that end, Teva and the Acquired Actavis Entities hereby designate materials in this production – which contain proprietary, trade secret, and confidential business and commercial information – as "CONFIDENTIAL" or "HIGHLY CONFIDENTIAL."

Please do not hesitate to contact me at the number above if you have any questions.

Morgan, Lewis & Bockius LLP

1701 Market Street
Philadelphia, PA 19103-2921
United States

T +1.215.963.5000
F +1.215.963.5001

February 8, 2019

Page 2

Very Truly Yours,

/s/ Rebecca J. Hillyer

Rebecca J. Hillyer

c: *via e-mail*
 Steven Reed, Esq.
 Wendy West Feinstein, Esq.
 All liaison counsel

EXHIBIT H

Shephard, Jr., Richard G.

From: Shephard, Jr., Richard G.
Sent: Thursday, February 07, 2019 5:09 PM
To: Shoshtari, Adam M. (SHB); Oot, Patrick L. (SHB)
Cc: Feinstein, Wendy West; Hillyer, Rebecca J.; Hammoud, Adam; Jacobs, Evan K.
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Patrick and Adam,

I hope this note finds you well. As you know, we represent Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Actavis LLC; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; and Watson Laboratories, Inc. (collectively, the "Teva Defendants") in the Opiate MDL.

Our apologies in advance, but as you are likely aware, Plaintiffs in the MDL have requested that we request from IQVIA any reports, work product, and communications with any of the Teva Defendants related to any SOM-related services provided to any of the Teva Defendants by Cegedim, Dendrite, Cegedim Dendrite, BuzzeoPDMA (collectively, the "Buzzeo-related entities") and/or IQVIA. Thus, can IQVIA please provide us:

- 1) Any reports or work product related to SOM consulting services provided to the Teva Defendants by any of the Buzzeo-related entities and/or IQVIA; and
- 2) All existing communications concerning SOM system audits, SOM design, and Suspicious Order Monitoring, between any of the Buzzeo-related entities and/or IQVIA and any of the Teva Defendants.

Also, we wanted to inform you that the Teva Defendants do not object to IQVIA producing any responsive information that is subject to Plaintiffs' subpoena.

We understand that this is not a simple request to fulfil. We very much appreciate your assistance.

Best,
Rich

Richard G. Shephard, Jr.

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.4899 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

richard.shephard@morganlewis.com | www.morganlewis.com

Assistant: Barbara J. Yuknick | +1.215.963.5410 | barbara.yuknick@morganlewis.com

From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>
Sent: Tuesday, January 15, 2019 8:46 AM
To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Thanks, Adam. I appreciate the update.

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Tuesday, January 15, 2019 7:31 AM

To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Evan—

I hope all is well!

IQVIA has located additional Buzzeo and Cegedim Dendrite agreements. We are in the process of redacting pricing information (as per standard practice) and should have these available for you to download (via a secure link) tomorrow.

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Shoshtari, Adam M. (SHB)

Sent: Wednesday, January 9, 2019 10:42 PM

To: 'Jacobs, Evan K.' <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <oot@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Hi Evan—

These will be shared with you (via Epiq) tomorrow.

Have a nice evening!

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>

Sent: Wednesday, January 9, 2019 10:12 PM

To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Adam,

Thanks for these documents. On our initial review, it looks like these contracts all relate to work with Buzzeo. Can IQVIA also provide the Teva Defendants (Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Actavis Pharma, Inc., Watson Laboratories, Inc. and Actavis LLC) with its reasonable accessible contracts/engagement agreements outside of just Buzzeo (e.g., contracts with IQVIA/IMS).

This was the request we made on December 14 in response to Patrick's December 7 letter offering to provide these contracts.

Thank you very much for your assistance.

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Monday, January 07, 2019 5:33 PM

To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Evan—

As previously requested, you will be receiving a secure link and password in order to download the readily accessible agreements. These will come in **two separate e-mails**, and should be distributed shortly. We are doing another follow-up with the client later this week, but this is what we have located after a reasonable search. I will be in touch as to whether you should be expecting anything further.

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Shoshtari, Adam M. (SHB)
Sent: Friday, January 4, 2019 3:31 PM
To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <oot@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Hi Evan—

We are still working with our client on your request, but hope to have information for you early next week.

I will follow-up as soon as possible.

Have a nice weekend!

Best,

Adam M. Shoshtari
Staff Attorney
Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>
Sent: Thursday, January 3, 2019 9:16 AM
To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>
Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J. <rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>
Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

Thanks, Adam. Much appreciated. Just to clarify, in addition to the Buzzeo related agreements we are also interested in any other agreements/statements of work/engagements that IQVIA has been able to identify based on their reasonable search (we sent an email on December 14 in response to Patrick's Dec. 7 letter requesting agreements generally) . We very much appreciate your assistance.

Happy New Year!

Evan

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Thursday, January 03, 2019 9:11 AM

To: Jacobs, Evan K. <evan.jacobs@morganlewis.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: RE: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Evan—

Happy New Year!

We are working on your request and I will follow-up tomorrow!

In addition, and per our objections, we have directed Plaintiffs to contact Defendants and right now, have not agreed to produce any information directly to Plaintiffs. The goal of our notice was to inform IQVIA clients of the request, identify the engagements that we are aware of after a reasonable search and to help clients respond from their own sources.

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



From: Jacobs, Evan K. <evan.jacobs@morganlewis.com>

Sent: Monday, December 31, 2018 10:46 AM

To: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>; Oot, Patrick L. (SHB) <OOT@shb.com>

Cc: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>; Hillyer, Rebecca J.

<rebecca.hillyer@morganlewis.com>; Shephard, Jr., Richard G. <richard.shephard@morganlewis.com>; Hammoud, Adam <adam.hammoud@morganlewis.com>

Subject: FW: In re National Prescription Opiate Litigation, MDL No. 2804

Adam and Patrick,

Happy New Year! Thanks for the information in the attached letters. We are continuing to work with our client to identify these agreements, but have not been able to do so yet. Are you able to send copies of the Agreements/Statement of Work that are referenced in your letters? In addition, to the extent you may be producing work product from these engagements, could you please send us copies of what you plan to produce?

Happy to discuss if you have any questions. Thanks for all of your assistance,

Evan

Evan K. Jacobs

Morgan, Lewis & Bockius LLP

1701 Market Street | Philadelphia, PA 19103-2921

Direct: +1.215.963.5329 | Main: +1.215.963.5000 | Fax: +1.215.963.5001

evan.jacobs@morganlewis.com | www.morganlewis.com

Assistant: Elizabeth M. Parker | +1.215.963.4820 | elizabeth.parker@morganlewis.com

From: Shoshtari, Adam M. (SHB) <ASHOSHTARI@shb.com>

Sent: Wednesday, December 19, 2018 8:35 PM

To: Feinstein, Wendy West <wendy.feinstein@morganlewis.com>

Cc: Oot, Patrick L. (SHB) <OOT@shb.com>

Subject: In re National Prescription Opiate Litigation, MDL No. 2804

[EXTERNAL EMAIL]

Hi Wendy—

See attached on behalf of IQVIA, Inc.

Happy Holidays!

Best,

Adam M. Shoshtari

Staff Attorney

Shook, Hardy & Bacon L.L.P.

202.662.4872 | ashoshtari@shb.com



Mail Gate made the following annotations on Wed Dec 19 2018 19:35:11

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

DISCLAIMER

This e-mail message is intended only for the personal use of the recipient(s) named above. This message may be an attorney-client communication and as such privileged and confidential and/or it may include attorney work product. If you are not an intended recipient, you may not review, copy or distribute this message. If you have received this communication in error, please notify us immediately by e-mail and delete the original message.

Mail Gate made the following annotations on Thu Jan 03 2019 08:10:54

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

Mail Gate made the following annotations on Mon Jan 07 2019 16:32:31

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

Mail Gate made the following annotations on Tue Jan 15 2019 06:31:21

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. Thank you.

EXHIBIT I



February 15, 2019

Patrick L. Oot

VIA ELECTRONIC MAIL

Wendy Feinstein
Partner
Morgan Lewis
One Oxford Centre, 32nd Fl.
Pittsburgh, PA 15219
T: 412-560-7455
E: wendy.feinstein@morganlewis.com

1155 F Street, N. W., Suite 200
Washington, D.C. 20004
t 202.783.8400
dd 202.639.5645
f 202.783.4211
oot@shb.com

Re: IQVIA's clients affected by the *In re National Prescription Opiate Litigation*, MDL No. 2804 in the Northern District of Ohio

Dear Wendy:

We write you to confirm that on behalf of IQVIA, Shook, Hardy & Bacon, LLP has received requests from certain Defendant manufacturers, distributors, retailers, and others ("Clients") seeking that IQVIA provide Clients with documents regarding their Suspicious Order Monitoring ("SOM") engagement with BuzzeoPDMA, LLC, Cegedim, Dendrite, and Cegedim Dendrite ("Buzzeo-related entities"). We understand that Clients' requests seek documents in response to Plaintiffs' demands in the *In re National Prescription Opiate Litigation*, MDL No. 2804 litigation in the Northern District of Ohio.

On September 14, 2018, IQVIA properly objected to Plaintiffs' Rule 45 subpoena but agreed to work with Clients to assist them in fulfilling their discovery obligations if such requests did not present an undue hardship or burden on IQVIA, which is not a party in this litigation. Over the last few months, IQVIA assisted Clients in fulfilling their productions related to sales and prescription data, and it is our understanding that the PEC has conveyed to the Court that Plaintiffs are satisfied with Clients' sales and prescription data productions. Now, all that is left are the SOM-related requests. This letter addresses those requests.

Since August 2018, Shook has worked diligently with IQVIA to identify Defendants' SOM-related engagements. In that regard, efforts to locate SOM-related engagements have been a significant burden as no single employee, data source or location exists that contains SOM-related engagement materials. The search for SOM-related information for multiple Clients has required, among other things, hundreds of hours of IQVIA employee and outside counsel time that has included, but is not limited to, disruptive employee interviews, document collection, and significant manual line-by-line,



page-by-page analysis for necessary redactions in order to protect IQVIA's confidential commercial information. As Clients have reviewed their own repositories and found gaps or deficiencies, Clients have requested IQVIA to fill those gaps, and IQVIA diligently has endeavored to do so, to the extent the documents are readily accessible and still exist.

February 15, 2019
Page 2

In our January 29, 2019 letter to the PEC, we summarized the results of IQVIA's efforts. IQVIA continues to provide Clients with information, upon request, to the extent that it still exists, on a first-in-first-out basis:

- On January 7, 2019, IQVIA began providing Clients with readily accessible agreements and statements of work ("SOWs") with Buzzeo-related entities via a secure download link and password.
- On February 11, 2019, IQVIA began providing Clients with readily-accessible deliverables with Buzzeo-related entities via a secure download link and password.
- By February 22, 2019, barring any unforeseen circumstances, IQVIA will provide Clients with the final set of readily-accessible deliverables with Buzzeo-related entities via a secure download link and password.

Recently, in addition to requests for contracts, SOWs and deliverables, IQVIA has received requests for *all* existing communications between Buzzeo-related entities and Defendants. On September 14, 2018, in IQVIA's Responses and Objections to Plaintiffs' Rule 45 Subpoena, IQVIA objected to this request, as it is overly broad, not proportional to the needs of the case, and seeks to impose undue burden and expense on a non-party for what is likely duplicative information. Instead, we agreed to cooperate with Clients on a cohesive and targeted approach to identify information within the scope of discovery and provide Clients with what is proportional to the needs of a case from a non-party. IQVIA's cohesive and targeted approach included contracts, SOWs, and deliverables and asked Clients to tell IQVIA what they believe might be missing.

As we have previously conveyed, parties must search their own document repositories, including e-mail sources before burdening a non-party. *See* Fed. R. Civ. P. 45(d)(1); *see also Waite, Schneider, Bayless & Chesley Co. v. Davis*, No.1:11-cv-0851, 2013 WL 146362, at *4-5 (D.D. Ohio Jan. 14, 2013); *In re CareSource Mgmt. Grp. Co.*, 289 F.R.D. 251, 253-54 (S.D. Ohio Jan. 3 2013) (quashing non-party subpoena because "[Plaintiff] must first establish that it cannot obtain the discoverable information from its party-opponent before subpoenaing those documents from a non-party"); *Musarra v. Digital Dash, Inc.*, No. 2:05-cv545, 2008 WL 4758699, at *3-4 (S.D. Ohio Oct. 30, 2008) (refusing to require non-party to produce documents when they were available from a party to the litigation); *Recycled Paper Greetings v. Davis*, No. 1:08—

mc—13, 2008 WL 440458, at *4-5 (N.D. Ohio Feb. 13, 2008) (granting a motion to quash subpoena, in part, because “the vast majority of the relevant documents” could have or had been produced by a party to the litigation).

Parties in the litigation, not IQVIA, are the best source for this information. *See* Fed. R. Civ. P. 26(B)(2)(C)(i) (the court must limit the frequency or extent of discovery allowed by these rules or by local rule if it determines that “discovery sought is unreasonably cumulative or duplicative, or can be obtained from some other source that is more convenient, less burdensome, or less expensive”); *see also* Fed. R. Civ. P. 45(d)(1) (“A party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena.”).

February 15, 2019
Page 3

IQVIA has objected and continues to object to the production of likely duplicative e-mail correspondence. The unreasonable burden and expense of searching for, collecting, processing, reviewing and producing e-mail messages for multiple SOM Clients will only inflict costs of exponential magnitude on IQVIA, a non-party, when it is far more efficient, less burdensome and proportional for each individual Client to first search its own e-mail repositories. Forcing this undue burden on IQVIA violates the Rules and common sense.

In addition, IQVIA did not participate in the development of the ESI Protocol, negotiate the Protective Order, or negotiate the search terms to be applied in this litigation. *See United States v. Columbia Broad. Sys., Inc.*, 666 F.2d 364, 371 (9th Cir. 1982) (because “[n]onparty witnesses are powerless to control the scope of litigation and discovery, [they] should not be forced to subsidize an unreasonable share of the costs of a litigation to which they are not a party.”). To embark upon a duplicative e-mail fishing expedition beyond the cohesive and targeted approach that IQVIA has undertaken would cost hundreds of thousands of dollars, if not millions, and the expenditure of significant internal resources, that a non-party should not be forced to bear.

It is our understanding that the PEC has asked Defendants if they have produced all existing communications in their possession concerning SOM between any of the Buzzeo-related entities and Clients. IQVIA understands that Defendants are in the process of confirming the completeness of their productions to the PEC. At this time, Defendants have not identified to IQVIA any lost, missing or deficient e-mail productions from Defendants to the PEC and IQVIA does not believe that inflicting duplicative discovery of exponential effort is warranted for a non-party to this litigation. Accordingly, prior to requesting IQVIA to produce all e-mail communications, Defendants should first turn to their own internal resources to identify and produce relevant e-mails. If they have not done so already, Defendants should identify their own custodians, and search criteria to locate SOM-related communications before propounding IQVIA with burdensome discovery.

SHOOK
HARDY & BACON

IQVIA has undertaken significant discovery efforts to assist Clients in satisfying their discovery obligations in response to Plaintiffs' requests. IQVIA will continue to do so, as appropriate and consistent with its reasonable objections. We believe the approach taken by IQVIA in producing to Clients any contracts and deliverables, upon request, is consistent with the Special Master's instructions and undoubtedly has been working.

February 15, 2019
Page 4

IQVIA will continue to update our Clients on the status of the efforts described above in the coming days, and I am happy to address any questions or concerns.

Best regards,

A handwritten signature in blue ink that reads "Patrick Oot". The signature is written in a cursive, flowing style.

Patrick L. Oot
Partner

EXHIBIT J

**List of Identified Communications Between IQVIA and the Teva Defendants Concerning
SOMS by Bates Begin Number**

Acquired_Actavis_00191600
Acquired_Actavis_00191601
Acquired_Actavis_00375652
Acquired_Actavis_00377577
Acquired_Actavis_00602333
Acquired_Actavis_00602336
Acquired_Actavis_00602339
Acquired_Actavis_00617815
Acquired_Actavis_00617820
Acquired_Actavis_00737366
Acquired_Actavis_00737367
Acquired_Actavis_00737368
Acquired_Actavis_00783295
Acquired_Actavis_00795992
Acquired_Actavis_00795994
Acquired_Actavis_00807765
Acquired_Actavis_00807766
Acquired_Actavis_00809992
Acquired_Actavis_00809993
Acquired_Actavis_00810370
Acquired_Actavis_00814187
Acquired_Actavis_00814188
Acquired_Actavis_00837504
Acquired_Actavis_00837506
Acquired_Actavis_00837507
Acquired_Actavis_00837508
Acquired_Actavis_00837509
Acquired_Actavis_00837510
Acquired_Actavis_00837511
Acquired_Actavis_01117571
Acquired_Actavis_01117573
Acquired_Actavis_01117590
Acquired_Actavis_01131613

Acquired_Actavis_01131619
Acquired_Actavis_01131621
Acquired_Actavis_01131630
Acquired_Actavis_01363036
Acquired_Actavis_01370513
Acquired_Actavis_01370519
Acquired_Actavis_01371138
Acquired_Actavis_01383792
Acquired_Actavis_01383794
Acquired_Actavis_01383813
Acquired_Actavis_01509230
Acquired_Actavis_01509254
Acquired_Actavis_01509388
Acquired_Actavis_01509389
Acquired_Actavis_01509391
Acquired_Actavis_01509407
Acquired_Actavis_01509410
Acquired_Actavis_01512007
Acquired_Actavis_01512009
Acquired_Actavis_01512173
Acquired_Actavis_01621003
Acquired_Actavis_01675295
Acquired_Actavis_01805077
Acquired_Actavis_01805078
Acquired_Actavis_02119760
Acquired_Actavis_02235410
Acquired_Actavis_02235421
Acquired_Actavis_02476237
TEVA_MDL_A_01042641
TEVA_MDL_A_01042809
TEVA_MDL_A_01060005
TEVA_MDL_A_01060849
TEVA_MDL_A_01086338
TEVA_MDL_A_01086339
TEVA_MDL_A_01451327
TEVA_MDL_A_01453770
TEVA_MDL_A_01453772
TEVA_MDL_A_01453801

TEVA_MDL_A_01453824
TEVA_MDL_A_01453842
TEVA_MDL_A_01453946
TEVA_MDL_A_01453947
TEVA_MDL_A_01454021
TEVA_MDL_A_01454022
TEVA_MDL_A_01454031
TEVA_MDL_A_01454033
TEVA_MDL_A_01454675
TEVA_MDL_A_01454676
TEVA_MDL_A_01455047
TEVA_MDL_A_01455048
TEVA_MDL_A_01455122
TEVA_MDL_A_01455124
TEVA_MDL_A_01455126
TEVA_MDL_A_01455127
TEVA_MDL_A_01455129
TEVA_MDL_A_01456483
TEVA_MDL_A_01456484
TEVA_MDL_A_01456486
TEVA_MDL_A_01456975
TEVA_MDL_A_01456992
TEVA_MDL_A_01456993
TEVA_MDL_A_01457010
TEVA_MDL_A_01457011
TEVA_MDL_A_01457015
TEVA_MDL_A_01457297
TEVA_MDL_A_01457298
TEVA_MDL_A_01457733
TEVA_MDL_A_01457735
TEVA_MDL_A_01458087
TEVA_MDL_A_01458385
TEVA_MDL_A_01458570
TEVA_MDL_A_01458571
TEVA_MDL_A_01463487
TEVA_MDL_A_01463532
TEVA_MDL_A_01463546
TEVA_MDL_A_01463547

TEVA_MDL_A_01463548
TEVA_MDL_A_01463554
TEVA_MDL_A_01463854
TEVA_MDL_A_01463855
TEVA_MDL_A_01463870
TEVA_MDL_A_01464026
TEVA_MDL_A_01464031
TEVA_MDL_A_01464033
TEVA_MDL_A_01464036
TEVA_MDL_A_01464037
TEVA_MDL_A_01464038
TEVA_MDL_A_01464039
TEVA_MDL_A_01464040
TEVA_MDL_A_01464050
TEVA_MDL_A_01464051
TEVA_MDL_A_01464244
TEVA_MDL_A_01464245
TEVA_MDL_A_01464251
TEVA_MDL_A_01464264
TEVA_MDL_A_01465343
TEVA_MDL_A_01465344
TEVA_MDL_A_01465525
TEVA_MDL_A_01469895
TEVA_MDL_A_01469951
TEVA_MDL_A_01471128
TEVA_MDL_A_01867031
TEVA_MDL_A_02064480
TEVA_MDL_A_02288312
TEVA_MDL_A_02288316
TEVA_MDL_A_02288320
TEVA_MDL_A_02330850
TEVA_MDL_A_02330852
TEVA_MDL_A_02331027
TEVA_MDL_A_02331028
TEVA_MDL_A_02331034
TEVA_MDL_A_02331070
TEVA_MDL_A_02331086
TEVA_MDL_A_02331101

TEVA_MDL_A_02331127
TEVA_MDL_A_02331179
TEVA_MDL_A_02331180
TEVA_MDL_A_02331183
TEVA_MDL_A_02331185
TEVA_MDL_A_02331186
TEVA_MDL_A_02331299
TEVA_MDL_A_02331300
TEVA_MDL_A_02331301
TEVA_MDL_A_02331302
TEVA_MDL_A_02331308
TEVA_MDL_A_02331310
TEVA_MDL_A_02331314
TEVA_MDL_A_02331320
TEVA_MDL_A_02331369
TEVA_MDL_A_02331370
TEVA_MDL_A_02331378
TEVA_MDL_A_02331379
TEVA_MDL_A_02331381
TEVA_MDL_A_02331410
TEVA_MDL_A_02331412
TEVA_MDL_A_02331421
TEVA_MDL_A_02331422
TEVA_MDL_A_02331423
TEVA_MDL_A_02331425
TEVA_MDL_A_02331426
TEVA_MDL_A_02331428
TEVA_MDL_A_02331465
TEVA_MDL_A_02331466
TEVA_MDL_A_02331498
TEVA_MDL_A_02331499
TEVA_MDL_A_02331937
TEVA_MDL_A_02331938
TEVA_MDL_A_02335004
TEVA_MDL_A_02335005
TEVA_MDL_A_02335006
TEVA_MDL_A_02336532
TEVA_MDL_A_02336533

TEVA_MDL_A_02336702
TEVA_MDL_A_02336703
TEVA_MDL_A_02336741
TEVA_MDL_A_02336745
TEVA_MDL_A_02336746
TEVA_MDL_A_02336748
TEVA_MDL_A_02336750
TEVA_MDL_A_02336766
TEVA_MDL_A_02336770
TEVA_MDL_A_02336771
TEVA_MDL_A_02336773
TEVA_MDL_A_02336775
TEVA_MDL_A_02336787
TEVA_MDL_A_02336788
TEVA_MDL_A_02336789
TEVA_MDL_A_02336790
TEVA_MDL_A_02336796
TEVA_MDL_A_02336798
TEVA_MDL_A_02336802
TEVA_MDL_A_02336808
TEVA_MDL_A_02336823
TEVA_MDL_A_02336824
TEVA_MDL_A_02336846
TEVA_MDL_A_02336847
TEVA_MDL_A_02336924
TEVA_MDL_A_02336925
TEVA_MDL_A_02336954
TEVA_MDL_A_02336955
TEVA_MDL_A_02336968
TEVA_MDL_A_02336969
TEVA_MDL_A_02336973
TEVA_MDL_A_02336974
TEVA_MDL_A_02337011
TEVA_MDL_A_02337012
TEVA_MDL_A_02337225
TEVA_MDL_A_02337226
TEVA_MDL_A_02337230
TEVA_MDL_A_02337243

TEVA_MDL_A_02338143
TEVA_MDL_A_02338239
TEVA_MDL_A_02476047
TEVA_MDL_A_02536844
TEVA_MDL_A_02540172
TEVA_MDL_A_02540173
TEVA_MDL_A_02540202
TEVA_MDL_A_02540221
TEVA_MDL_A_02540244
TEVA_MDL_A_02540278
TEVA_MDL_A_02540279
TEVA_MDL_A_02543428
TEVA_MDL_A_02543429
TEVA_MDL_A_02543430
TEVA_MDL_A_02543431
TEVA_MDL_A_02543432
TEVA_MDL_A_02543433
TEVA_MDL_A_02543434
TEVA_MDL_A_02543435
TEVA_MDL_A_02543436
TEVA_MDL_A_02543437
TEVA_MDL_A_02543438
TEVA_MDL_A_02543447
TEVA_MDL_A_02543457
TEVA_MDL_A_02543469
TEVA_MDL_A_02543480
TEVA_MDL_A_02543481
TEVA_MDL_A_02543482
TEVA_MDL_A_02543483
TEVA_MDL_A_02543492
TEVA_MDL_A_02543502
TEVA_MDL_A_02543514
TEVA_MDL_A_02543525
TEVA_MDL_A_02543526
TEVA_MDL_A_02543814
TEVA_MDL_A_02543815
TEVA_MDL_A_02546025
TEVA_MDL_A_02546026

TEVA_MDL_A_02943890
TEVA_MDL_A_03072214
TEVA_MDL_A_03072259
TEVA_MDL_A_03158257
TEVA_MDL_A_03158258
TEVA_MDL_A_03158426
TEVA_MDL_A_03158428
TEVA_MDL_A_03158434
TEVA_MDL_A_03158440
TEVA_MDL_A_03158441
TEVA_MDL_A_03158442
TEVA_MDL_A_03158443
TEVA_MDL_A_03158444
TEVA_MDL_A_03158450
TEVA_MDL_A_03158460
TEVA_MDL_A_03158462
TEVA_MDL_A_03159516
TEVA_MDL_A_03159517
TEVA_MDL_A_03159518
TEVA_MDL_A_03159519
TEVA_MDL_A_03159526
TEVA_MDL_A_03159527
TEVA_MDL_A_03478588
TEVA_MDL_A_03478589
TEVA_MDL_A_03478590
TEVA_MDL_A_03478598
TEVA_MDL_A_03478599
TEVA_MDL_A_03478607
TEVA_MDL_A_03478615
TEVA_MDL_A_03478616
TEVA_MDL_A_03478617
TEVA_MDL_A_03952284
TEVA_MDL_A_03952285
TEVA_MDL_A_06442206
TEVA_MDL_A_06442207
TEVA_MDL_A_06618218
TEVA_MDL_A_06618219
TEVA_MDL_A_06618645

TEVA_MDL_A_06618646
TEVA_MDL_A_06618647
TEVA_MDL_A_06618651
TEVA_MDL_A_06618655
TEVA_MDL_A_06618657
TEVA_MDL_A_06618660
TEVA_MDL_A_06645700
TEVA_MDL_A_06645702
TEVA_MDL_A_06645718
TEVA_MDL_A_06645725
TEVA_MDL_A_06645726
TEVA_MDL_A_08465911
TEVA_MDL_A_08935897
TEVA_MDL_A_09563040
TEVA_MDL_A_09563042
TEVA_MDL_A_09563044
TEVA_MDL_A_09563045
TEVA_MDL_A_09563147
TEVA_MDL_A_09563149
TEVA_MDL_A_09563150
TEVA_MDL_A_09563152
TEVA_MDL_A_09563153
TEVA_MDL_A_09563154
TEVA_MDL_A_09563454
TEVA_MDL_A_09563455
TEVA_MDL_A_09563456
TEVA_MDL_A_09563471
TEVA_MDL_A_09563472
TEVA_MDL_A_09563473
TEVA_MDL_A_09563503
TEVA_MDL_A_09563504
TEVA_MDL_A_09563505
TEVA_MDL_A_09563506
TEVA_MDL_A_09567301
TEVA_MDL_A_09567303
TEVA_MDL_A_09567925
TEVA_MDL_A_09567926
TEVA_MDL_A_09571649

TEVA_MDL_A_09571651
TEVA_MDL_A_09571653
TEVA_MDL_A_09571657
TEVA_MDL_A_09571661
TEVA_MDL_A_09571679
TEVA_MDL_A_09571681
TEVA_MDL_A_09571682
TEVA_MDL_A_09573255
TEVA_MDL_A_09573257
TEVA_MDL_A_09576598
TEVA_MDL_A_09576600
TEVA_MDL_A_09588193
TEVA_MDL_A_09588486
TEVA_MDL_A_09588487
TEVA_MDL_A_09588488
TEVA_MDL_A_09762586
TEVA_MDL_A_11477279
TEVA_MDL_A_11477280
TEVA_MDL_A_11477282
TEVA_MDL_A_12735135
TEVA_MDL_A_12738896
TEVA_MDL_A_12740529
TEVA_MDL_A_13647827